Marea linked its antibody to a 53% placebo-adjusted mean reduction in remnant cholesterol, positioning the biotech to enter phase 2b imminently.

Lankinen stopped seven of 11 shots in a 5-3 defeat against the Rangers on Saturday. The fifth goal was an empty-netter. Lankinen allowed three goals on six shots in a disastrous third period.

Vancouver Canucks goalie Kevin Lankinen agreed to a five-year contract extension Friday with an average annual value of $4.5 million.

The Vancouver Canucks announced Friday that they had agreed to terms with goaltender Kevin Lankinen on a five-year, $22.5 million ($4.5 million annual average value) extension. Lankinen, who was a ...

Kevin Lankinen signed a five-year, $22.5 million contract with the Vancouver Canucks on Friday. The deal, which begins next season, has an average annual value of $4.5 million.

By signing Lankinen to a five-year deal, however, the Canucks are looking to him as a key piece of their goalie duo for the future. He’ll be 35 when the contract ends.

New York Italian staple Marea has expanded to the West Coast for the first time, opening a second location in Beverly Hills, California.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-gene ...

Vancouver Canucks goaltender Kevin Lankinen has been doing a good job of holding down the fort since the start of the season with Thatcher Demko sidelined.

Kevin Lankinen delivers an exceptional goaltending show, leading the Vancouver Canucks to a 2-0 road win against Boston. Lankinen is now 8-0 on the road.

It was the point in Kevin Lankinen's career where he had to bet on himself. While it wasn't looking good for him all summer after doing so, it ended up working out and the risk is paying off now ...